GlassScriptPhysician profile
Nasim Mastouri
NPI 1710121132
$6,528.61
in general payments reported to CMS, 2019-2025
36 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2021: $536 · 2022: $909 · 2023: $1,283 · 2024: $1,493 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,691 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.29 |
| Education | $274.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $615.70 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $566.12 | 2021-2025 | Acthar |
| Vifor Pharma, INC. | $545.62 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $543.69 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $506.17 | 2022-2023 | Lupkynis |
| Amgen INC. | $460.58 | 2019-2025 | Tavneos, Repatha |
| Otsuka America Pharmaceutical, INC. | $419.67 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $394.56 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $389.55 | 2023-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $250.88 | 2019-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.17 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $205.91 | 2019-2025 | Ozempic, Rybelsus |
| Alexion Pharmaceuticals, INC. | $197.69 | 2019-2024 | Ultomiris |
| Akebia Therapeutics INC | $161.19 | 2019 | |
| Ardelyx, INC. | $157.37 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $151.69 | 2019-2024 | Renal - Acute, Renal - Extraneal Solution |
| Renalytix Ai, INC. | $103.44 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Lilly USA, LLC | $76.54 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Mallinckrodt Enterprises LLC | $75.42 | 2019 | |
| Daiichi Sankyo INC. | $68.33 | 2019-2023 | Injectafer |
| Madrigal Pharmaceuticals | $55.71 | 2025 | Rezdiffra |
| Pfizer INC. | $48.19 | 2024 | |
| Fresenius USA Marketing, INC. | $42.22 | 2023-2025 | Velphoro, Velphoro |
| Janssen Pharmaceuticals, INC | $29.72 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.73 | 2019 | |
| Bard Peripheral Vascular, INC. | $23.95 | 2023 | Wavelinq |
| Xeris Pharmaceuticals, INC. | $23.55 | 2025 | Keveyis |
| Abbvie INC. | $23.05 | 2021 | |
| Nxstage Medical, INC. | $20.61 | 2019 | |
| Shire North American Group INC | $19.69 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.77 | 2025 | Lifevest |
| Shield Therapeutics INC | $17.75 | 2023 | Accrufer |
| Ani Pharmaceuticals, INC. | $16.74 | 2023 | Purified Cortrophin Gel |
| Urovant Sciences INC | $15.75 | 2022 | |
| Travere Therapeutics, INC. | $14.85 | 2023-2025 | Filspari |
| Takeda Pharmaceuticals U.S.A., INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasim Mastouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.